Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Astria Therapeutics Inc (ATXS) is a biopharmaceutical innovator developing monoclonal antibody therapies for rare immunological conditions like hereditary angioedema and atopic dermatitis. This page aggregates all official company announcements and verified news updates for stakeholders tracking its preclinical pipeline and scientific advancements.
Investors and researchers will find timely updates on clinical developments, regulatory milestones, and strategic partnerships. Our curated feed includes progress reports on key candidates like plasma kallikrein inhibitors and OX40 antagonists, along with analyses of their potential impact on underserved patient populations.
Content spans trial design announcements, patent filings, executive commentary, and peer-reviewed research collaborations. All materials are vetted for accuracy and presented in chronological order to help users track the company's evolving position in the rare disease therapeutics market.
Bookmark this page for streamlined access to ATXS's latest scientific disclosures and corporate developments. Check regularly for updates on antibody engineering breakthroughs and preclinical validation studies shaping the future of immune disorder treatments.
Astria Therapeutics (NASDAQ: ATXS), a biopharmaceutical company specializing in allergic and immunologic disease therapies, has announced that CEO Jill C. Milne, Ph.D. will participate in a fireside chat at the Jefferies Global Healthcare Conference. The presentation is scheduled for June 4th at 1:25pm ET. The event will be accessible via webcast, with a replay available on the company's investor website for 30 days following the presentation.
Astria Therapeutics (NASDAQ: ATXS) has announced its upcoming presentation at the 14th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary. The presentation, scheduled for May 31, 2025, at 2:45 PM CET, will be delivered by Dr. Marc A. Riedl, Professor of Medicine and Clinical Director of the U.S. HAEA Angioedema Center at UC San Diego.
The presentation will focus on safety and efficacy data from the Phase 1a and Phase 1b/2 trials of navenibart in treating Hereditary Angioedema (HAE). The session, titled "Navenibart for Hereditary Angioedema (HAE): Analysis of Safety, Pharmacokinetic, and Pharmacodynamic Data From Phase 1a and Phase 1b/2 ALPHA-STAR Trial," will take place at the Ensana Thermal Hotel Margitsziget.
Astria Therapeutics (NASDAQ:ATXS) reported Q1 2025 financial results and provided updates on its key programs. The company's lead candidate navenibart is currently in the ALPHA-ORBIT Phase 3 trial for hereditary angioedema (HAE), with top-line results expected in early 2027. Previous Phase 1b/2 trial results showed 90-95% reduction in monthly attack rates. The company is also developing STAR-0310, a monoclonal antibody for atopic dermatitis, with Phase 1a results expected in Q3 2025.
Financial highlights for Q1 2025:
- Cash position: $295.1M (vs $328.1M in Q4 2024)
- Net loss: $33.7M ($0.58 per share)
- R&D expenses: $27.8M
- G&A expenses: $9.2M
The company expects current cash to fund operations into mid-2027, covering the completion of the ALPHA-ORBIT Phase 3 trial and STAR-0310 Phase 1a trial.
Astria Therapeutics, a biopharmaceutical company developing therapies for allergic and immunologic diseases, has announced an upcoming presentation at the Citizens Life Sciences Conference.
The company's CEO, Jill C. Milne, Ph.D., will participate in a fireside chat scheduled for Wednesday, May 7th at 10:30am ET. Investors and interested parties can access the presentation through a live webcast link, with an archived replay remaining available on the company's website for 30 days after the event.
The presentation represents an opportunity for investors to gain insights into Astria's developments in the immunologic disease treatment space. The company, trading under the Nasdaq symbol ATXS, continues to maintain transparency with its stakeholders through participation in key industry events.
FAQ
What is the current stock price of Astria Therapeutics (ATXS)?
What is the market cap of Astria Therapeutics (ATXS)?
